SRPT — Sarepta Therapeutics, Inc.

—
Nasdaq · Health Care · Pharmaceuticals · CIK 873303 ·
Last close
$14.77
Market Cap
$1.58B
52W High
$24.68
52W Low
$14.59
ADV30
2,499,610
Next earnings
2026-11-05

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 381,351,000 192,839,000 -9,040,000 -28,461,000 3,166,066,000 472,760,000 1,637,213,000
Jun 2026 401,251,000 251,866,000 52,291,000 -4,890,000 3,188,512,000 571,148,000 1,660,714,000
Mar 2026 730,803,000 622,035,000 358,433,000 330,959,000 3,178,934,000 464,450,000 1,673,832,000
Dec 2025 442,934,000 44,226,000 -410,084,000 -282,847,000 3,349,703,000 801,282,000 2,209,081,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$111,008,000
Investing CF
$100,845,000
Financing CF
$-156,757,000
CapEx
$-36,037,000
Dividends Paid
—
Buybacks
$0
EPS Diluted TTM
$-2.90
As of
2026-11-08

Balance + Analyst (yfinance extras)

Retained Earnings
$-4,550,915,000
Inventory
$904,273,000
Receivables
$438,814,000
ST Investments
$217,341,000
EBIT TTM
$-59,290,000
Pretax Income TTM
$-130,920,000
Interest Exp TTM
$71,630,000
Analysts
22

Yahoo Snapshot (yfinance, live)

Total Revenue
$1,956,338,944
EBITDA
$23,756,000
Free Cash Flow
$109,313,752
Enterprise Value
$2,111,220,864
Total Cash
$878,776,000
Total Debt
$1,079,053,952
Shares Out
107,235,848
Trailing EPS
$0.02
Book Value
$14.26
ROE
-8.0%
ROA
-0.2%
Div Yield
0.00%

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 2,198,237,000 -657,772,000 -713,410,000 3,349,703,000 2,209,081,000 1,140,622,000 -205,479,000
Dec 2024 1,901,979,000 218,081,000 235,239,000 3,963,173,000 2,435,431,000 1,527,742,000 -205,787,000
Dec 2023 1,243,336,000 -267,824,000 -535,977,000 3,264,576,000 2,405,239,000 859,337,000 -500,993,000
Dec 2022 933,013,000 -536,201,000 -703,488,000 3,128,366,000 2,743,416,000 384,950,000 -325,346,000

TTM Snapshot

Revenues TTM
$1,974,344,000
NetIncome TTM
$-136,725,000
OpCashFlow TTM
—
Assets (Latest)
$3,188,512,000
Forward EPS
$2.33

Max Pain — expiry 2027-12-17

max pain strike: $7.50 · spot: $14.53 · call oi: 0 · put oi: 1,747
Expected Move to 2027-12-17: ±$8.90 (61.25%) — implied range $5.63 – $23.43 · ATM straddle on $15.00 strike

Peers — same industry

TickerNameMarket CapLastDaily %
KLRA Kailera Therapeutics, Inc. $1.58B $12.20 —
ANIP ANI PHARMACEUTICALS INC $1.59B $69.99 —
NRIX Nurix Therapeutics, Inc. $1.56B $14.24 —
PGEN PRECIGEN, INC. $1.54B $4.29 —
ADRX ADARx Pharmaceuticals, Inc. $1.53B $13.82 —

News headlines (Yahoo Finance, 1h cache)

DraftKings downgraded, Sarepta upgraded: Wall Street's top analyst calls
2026-11-10 14:46 · Yahoo
Sarepta Therapeutics Sees Transformational 2027 as Rare Disease Programs Advance
2026-11-09 22:12 · Yahoo
Learn Why The Bull Case For Sarepta Therapeutics Stock Could Change Following Raised Revenue Guidance
2026-11-07 11:14 · Yahoo
Sarepta (SRPT) Q3 2026 Earnings Call Transcript
2026-11-06 16:14 · Yahoo
Sarepta Therapeutics Q3 Earnings Call Highlights
2026-11-06 09:14 · Yahoo
Sarepta Therapeutics (SRPT) Q3 Earnings Lag Estimates
2026-11-06 00:00 · Yahoo
Compared to Estimates, Sarepta Therapeutics (SRPT) Q3 Earnings: A Look at Key Metrics
2026-11-05 23:30 · Yahoo
Sarepta Therapeutics: Q3 Earnings Snapshot
2026-11-05 22:09 · Yahoo
Sarepta Therapeutics Announces Third Quarter 2026 Financial Results and Recent Corporate Developments
2026-11-05 21:05 · Yahoo
Sarepta Therapeutics Inc (SRPT) Q3 2026 Earnings Call Highlights: Revenue Guidance Raised ...
2026-11-06 11:18 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.